You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Treatment of BRAF-Mutant Melanoma: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Aaron White.

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15–20% before the advent of immunotherapy. Treatment with immune checkpoint inhibitors has increased long-term survival outcomes in patients with advanced melanoma to as high as 50% although individual response can vary greatly. A mutation within the MAPK pathway leads to uncontrollable growth and ultimately develops into cancer. The most common driver mutation that leads to this characteristic overactivation in the MAPK pathway is the B-RAF mutation. Current combinations of BRAF and MEK inhibitors that have demonstrated improved patient outcomes include dabrafenib with trametinib, vemurafenib with cobimetinib or encorafenib with binimetinib. Treatment with BRAF and MEK inhibitors has met challenges as patient responses began to drop due to the development of resistance to these inhibitors which paved the way for development of immunotherapies and other small molecule inhibitor approaches to address this. Resistance to these inhibitors continues to push the need to expand our understanding of novel mechanisms of resistance associated with treatment therapies.

  • melanoma
  • metastatic
  • resistance
  • BRAF
  • immunotherapy
Please wait, diff process is still running!

References

  1. Miller, A.J.; Mihm, M.C., Jr. Melanoma. N. Engl. J. Med. 2006, 355, 51–65.
  2. American Cancer Society. Cancer Facts & Figures. 2019. Available online: (accessed on 22 November 2019).
  3. Dobry, A.S.; Zogg, C.K.; Hodi, F.S.; Smith, T.R.; Ott, P.A.; Iorgulescu, J.B. Management of metastatic melanoma: Improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol. Immunother. 2018, 67, 1833–1844.
  4. Albertini, M.R. The age of enlightenment in melanoma immunotherapy. J. Immunother. Cancer 2018, 6, 80.
  5. ASCO Post. Long-Term Survival Outcomes with New Treatments for Advanced Melanoma: Questions Still in Need of Answers. Available online: (accessed on 30 January 2020).
  6. Liu, Y.; Sheikh, M.S. Melanoma: Molecular pathogenesis and therapeutic management. Mol. Cell. Pharmacol. 2014, 6, 228.
  7. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAPK kinase signaling pathways in cancer. Oncogene 2007, 26, 3279–3290.
  8. Millet, A.; Martin, A.R.; Ronoco, C.; Rocchi, S.; Benhida, R. Metastatic: Insights into the evolution of the treatments and future challenges. Med. Res. Rev. 2017, 37, 98–148.
  9. Cheng, L.; Lopez-Beltran, A.; Massari, F.; MacLennan, G.T.; Montironi, R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. Mod. Pathol. 2018, 31, 24–38.
  10. Kong, B.Y.; Carlino, M.S.; Menzies, A.M. Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Manag. 2016, 3, 33–45.
  11. American Cancer Society. Treating Melanoma Skin Cancer. Available online: (accessed on 22 November 2019).
  12. Shirley, M. Encorafenib and Binimetinib: First global approvals. Drugs 2018, 78, 1277–1284.
  13. Eroglu, Z.; Ribas, A. Combination therapy with BRAF and MEK inhibitors for melanoma: Latest evidence and place in therapy. Ther. Adv. Med. Oncol. 2016, 8, 48–56.
  14. Marconcini, R.; Spagnolo, F.; Stucci, L.S.; Ribero, S.; Marra, E.; Rosa, F.; Picasso, V.; Di Gurado, L.; Cimminiello, C.; Cavalieri, S.; et al. Current status and perspective in immunotherapy for metastatic melanoma. Oncotarget 2018, 9, 12452–12470.
  15. Ribas, A.; Lawrence, D.; Atkinson, V.; Agarwal, S.; Miller, W.H., Jr.; Carlino, M.S.; Fisher, R.; Long, G.V.; Hodi, F.S.; Tsoi, J.; et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 2019, 25, 936–940.
  16. Simeone, E.; Grimaldi, A.M.; Festino, L.; Vanella, V.; Palla, M.; Ascierto, P.A. Combination treatment of patients with BRAF-mutant melanoma: A new standard of care. BioDrugs 2017, 31, 51–61.
  17. Davies, M.A.; Kwong, L.N. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin. Cancer Res. 2013, 19, 5310–5319.
  18. Harris, A.L.; Lee, S.E.; Dawson, L.K.; Marlow, L.A.; Edenfield, B.H.; Durham, W.F.; Flotte, T.J.; Thompson, M.; Small, D.L.; Synnott, A.J. Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma. Oncotarget 2018, 9, 10905–10919.
  19. Aasen, S.N.; Parajuli, H.; Hoang, T.; Feng, Z.; Stokke, K.; Wang, J.; Roy, K.; Bjerkvig, R.; Knappskog, S.; Thorsen, F. Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. Int. J. Mol. Sci. 2019, 20, 4235.
  20. Schettini, F.; Santo, I.D.; Rea, C.G.; Placido, P.D.; Formisano, L.; Giuliano, M.; Arpino, G.; Laurentiis, M.D.; Puglisi, F.; Placido, S.D.; et al. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol. 2018, 8, 608.
  21. Kollmann, K.; Briand, C.; Bellutti, F.; Schicher, N.; Blunder, S.; Zojer, M.; Hoeller, C. The interplay of CDK4 and CDK6 in melanoma. Oncotarget 2019, 10, 1346–1359.
  22. Lee, B.; McArthur, G.A. CDK4 inhibitors an emerging strategy for the treatment of melanoma. Melanoma Manag. 2015, 2, 255–266.
  23. Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front. Pharmacol. 2017, 8, 561.
  24. U.S. FDA. Available online: (accessed on 25 November 2019).
  25. Sundar, R.; Cho, B.C.; Brahmer, J.R.; Soo, R.A. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther. Adv. Med. Oncol. 2015, 7, 85–96.
  26. Opdivo (Nivolumab). Available online: (accessed on 25 November 2019).
  27. U.S. FDA. Available online: (accessed on 25 November 2019).
  28. Pfizer. Available online: (accessed on 25 November 2019).
  29. Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S. Safety and tumor responses with labrolizumab (Anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369, 134–144.
  30. Clinical Trials.gov. Avelumab in metastatic or locally advanced solid tumors (javelin solid tumor) (NCT01772004). Available online: (accessed on 25 November 2019).
  31. U.S. FDA. Available online: (accessed on 25 November 2019).
  32. WHO Drug Information. Available online: (accessed on 25 November 2019).
  33. Clinical trials.gov. A study to assess the safety, tolerability and anti-tumour activity of ascending doses of selumetinib in combination with MEDI4736 and selumetinib in combination with MEDI4736 and tremelimumab in patients with advanced solid tumours (NCT02586987). Available online: (accessed on 25 November 2019).
  34. STAT. Roche scores first U.S. approval of immunotherapy for breast cancer. Available online: (accessed on 18 February 2020).
  35. Genetech. Tecentriq (Atezolizumab). Available online: (accessed on 25 November 2019).
  36. Clinical trials.gov. Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in melanoma: NEO-VC (NEO-VC) (NCT02303951). Available online: (accessed on 25 November 2019).
  37. Clinical trials.gov. A Study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAFv600 mutation-positive patients with metastatic or unresectable locally advanced melanoma (NCT02908672). Available online: (accessed on 25 November 2019).
  38. National Cancer Institute. Spratalizumab. Available online: (accessed on 27 January 2020).
  39. Clinical trials.gov. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors (NCT03891953). Available online: (accessed on 27 January 2020).
  40. Clinical trials.gov. Study of efficacy and safety of novel spartalizumab combinations in patients with previously treated unresectable or metastatic melanoma (PLATforM) (NCT03484923). Available online: (accessed on 27 January 2020).
  41. Clinical trials.gov. A study of the anti-PD1 antibody PDR001, in combination with dabrafenib and trametinib in advanced melanoma (COMBI-i) (NCT02967692). Available online: (accessed on 27 January 2020).
  42. Rowshanravan, B.; Halliday, N.; Sansom, D. CTLA-4: A moving target in immunotherapy. Blood 2018, 131, 58–67.
  43. Stamper, C.C.; Zhang, Y.; Tobin, J.F.; Erbe, D.V.; Ikemizu, S.; Davis, S.J.; Stahl, M.L.; Seehra, J.; Somers, W.S.; Mosyak, L. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001, 410, 608–611.
  44. Qureshi, O.S.; Zheng, Y.; Nakamura, K.; Attridge, K.; Manzotti, C.; Schmidt, E.M.; Baker, J.; Jeffery, L.E.; Kaur, S.; Briggs, Z. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332, 600–603.
  45. Esensten, J.H.; Helou, Y.A.; Chopra, G.; Weiss, A.; Bluestone, J.A. CD28 costimulation: From mechanism to therapy. Immunity 2016, 44, 973–988.
  46. Chan, D.V.; Gibson, H.M.; Aufiero, B.M.; Wilson, A.J.; Hafner, M.S.; Mi, Q.S.; Wong, H.K. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immunity 2014, 15, 25–32.
  47. Comin-Anduix, B.; Escuin-Ordinas, H.; Ibarrondo, F.J. Tremelimumab: Research and clinical development. OncoTargets Ther. 2016, 9, 1767–1776.
  48. Clinical trials.gov. Phase I clinical trial of Tremelimumab plus MEDI3617 in patients with unresectable stage III or stage IV melanoma (NCT02141542). Available online: (accessed on 26 November 2019).
  49. Clinical trials.gov. Tremelimumab and CP-870,893 in patients with metastatic melanoma (NCT01103635). Available online: (accessed on 26 November 2019).
  50. Wolchok, J.D.; Hodi, F.S.; Weber, J.S.; Allison, J.P.; Urba, W.J.; Robert, C.; O’Day, S.J.; Humphrey, R.; Berman, D.M.; Lonberg, N.; et al. Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. N. Y. Acad. Sci. 2013, 1291, 1–13.
  51. Clinical trials.gov. Trial of neoadjuvant ipilimumab followed by melphalan via isolated limb infusion for patients with unresectable in-transit extremity melanoma (NCT02115243). Available online: (accessed on 26 November 2019).
  52. Clinical trials.gov. Galectin inhibitor (GR-MD-02) and Ipilimumab in patients with metastatic melanoma (NCT02117362). Available online: (accessed on 26 November 2019).
  53. Clinical trials.gov. A Study of combination with TBI-1401(HF10) and Ipilimumab in Japanese patients with unresectable or metastatic melanoma (NCT03153085). Available online: (accessed on 26 November 2019).
  54. Clinical trials.gov. Phase II trial of stereotactic body radiotherapy followed by Ipilimumab in treating patients with stage IV melanoma (NCT01970527). Available online: (accessed on 26 November 2019).
  55. Yano, H.; Andrews, L.P.; Workman, C.J.; Vignali, D.A.A. Intratumoral regulatory T cells: Markers, subsets and their impact on anti-tumor immunity. Immunology 2019, 157, 232–247.
  56. Clinical trials.gov. Phase I study of BCD-145 (anti-CTLA-4) in patients with unresectable/metastatic melanoma (NCT03472027). Available online: (accessed on 26 November 2019).
  57. Clinical trials.gov. Selective HDAC6 inhibitor ACY-241 in combination with Ipilimumab and Nivolumab (NCT02935790). Available online: (accessed on 26 November 2019).
  58. Yamazaki, N.; Takenouchi, T.; Fujimoto, M.; Ihn, H.; Uchi, H.; Inozume, T.; Kiyohara, Y.; Uhara, H.; Nakagawa, K.; Furukawa, H.; et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother. Pharmacol. 2017, 79, 651–660.
  59. Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F.S.; Schachter, J.; Pavlick, A.C.; Lewis, K.D.; et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015, 16, 908–918.
  60. Robert, C.; Ribas, A.; Schachter, J.; Arance, A.; Grob, J.; Mortier, L.; Daud, A.; Carlino, M.; Mc Neil, C.M.; Lotem, M.; et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019, 20, 1239–1251.
  61. Ribas, A.; Butler, M.; Lutzky, J.; Lawrence, D.P.; Robert, C.; MillerGerald, W.; Linette, P.; Ascierto, P.A.; Kuzel, T.; Algazi, A.P.; et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 2015, 33, 3003.
  62. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab. JAMA Oncol. 2019, 5, 1411–1420.
  63. Sullivan, R.J.; Hamid, O.; Gonzalez, R.; Infante, J.R.; Patel, M.R.; Hodi, F.S.; Lewis, K.D.; Tawbi, H.A.; Hernandez, G.; Wongchenko, M.J.; et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 2019, 25, 929–935.
  64. Kirkwood, J.M.; Lorigan, P.; Hersey, P.; Hauschild, A.; Robert, C.; McDermott, D.; Marshall, M.A.; Gomez-Navarro, J.; Liang, J.Q.; Bulanhagui, C.A. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 2010, 16, 1042–1048.
  65. Weber, J.; Hamid, O.; Amin, A.; O’Day, S.; Masson, E.; Goldberg, S.M.; Williams, D.; Parker, S.M.; Chasalow, S.D.; Alaparthy, S.; et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013, 13, 7.
  66. Reilley, M.J.; Bailey, A.; Subbiah, V.; Janku, F.; Naing, A.; Falchook, G.; Karp, D.; Piha-Paul, S.; Tsimberidou, A.; Fu, S.; et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J. Immunother. Cancer 2017, 5, 35.
  67. Tarhini, A.; Lin, Y.; Lin, H.; Rahman, Z.; Vallabhaneni, P.; Mendiratta, P.; Pingpank, J.F.; Holtzman, M.P.; Yusko, E.C.; Rytlewski, J.A.; et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: Safety, efficacy and impact on T-cell repertoire. J. Immunother. Cancer 2018, 6, 112.
  68. Brohl, A.S.; Khushalani, N.I.; Eroglu, Z.; Markowitz, J.; Thapa, R.; Chen, Y.A.; Kudchadkar, R.; Weber, J.S. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J. Immunothr. Cancer 2016, 4, 85.
  69. Clinical trials.gov. A study of intratumoral injection of interlukin-2 and ipilimumab in patients with unresectable stages III-IV melanoma (NCT01672450). Available online: (accessed on 26 November 2019).
  70. Ray, A.; Williams, M.A.; Meek, S.M.; Bowen, R.C.; Grossmann, K.F.; Andtbacka, R.H.; Bowles, T.L.; Hyngstrom, J.R.; Leachman, S.A.; Grossman, D.; et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget 2016, 7, 64390–64399.
  71. Williams, N.L.; Wuthrick, E.J.; Kim, H.; Palmer, J.D.; Garg, S.; Eldredge-Hindy, H.; Daskalakis, C.; Feeney, K.J.; Mastrangelo, M.J.; Kim, L.J.; et al. Phase 1 study of Ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patient with brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2017, 99, 22–30.
  72. Wolchok, J.D.; Neyns, B.; Linette, G.; Negrier, S.; Lutzky, J.; Thomas, L.; Waterfield, W.; Schadendorf, D.; Smylie, M.; Guthrie, T., Jr.; et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11, 155–164.
  73. Di Giacomo, A.M.; Ascierto, P.A.; Queirolo, P.; Pilla, L.; Ridolfi, R.; Santinami, M.; Testori, A.; Simeone, E.; Guidoboni, M.; Maurichi, A.; et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the italian network for tumor biotherapy (NIBIT)-M1 phase II study. Ann. Oncol. 2015, 26, 798–803.
  74. Haag, G.M.; Zoernig, I.; Hassel, J.C.; Halama, N.; Dick, J.; Lang, N.; Podola, L.; Funk, J.; Ziegelmeier, C.; Juenger, S.; et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur. J. Cancer 2018, 90, 122–129.
  75. Amin, A.; Lawson, D.H.; Salama, A.K.S.; Koon, H.B.; Guthrie, T., Jr.; Thomas, S.S.; O’Day, S.J.; Shaheen, M.F.; Zhang, B.; Francis, S.; et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J. Immunother. Cancer 2016, 4, 44.
  76. Andtbacka, R.H.I.; Ross, M.I.; Agarwala, S.S.; Taylor, M.H.; Vetto, J.T.; Neves, R.I.; Daud, A.; Khong, H.T.; Ungerleider, R.S.; Tanaka, M. Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma. J. Clin. Oncol. 2018, 36, 9541.
  77. Ariyan, C.E.; Lefkowitz, R.A.; Panageas, K.; Callahan, M.K.; Misholy, O.; Bello, D.; Fisher, C.; Kotin, A.; Siegelbaum, R.; Coit, D.G.; et al. Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma. J. Clin. Oncol. 2014, 32, 9078.
  78. Yamazaki, N.; Kiyohara, Y.; Uhara, H.; Fukushima, S.; Uchi, H.; Shibagaki, N.; Tsutsumida, A.; Yoshikawa, S.; Okuyama, R.; Ito, Y.; et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol. 2015, 76, 997–1004.
  79. Clinical trials.gov. Ipilimumab+Temozolamide in metastatic melanoma (NCT01119508). Available online: (accessed on 26 November 2019).
  80. Patel, S.P.; Kim, D.W.; Bassett, R.L.; Cain, S.; Washington, E.; Hwu, W.J.; Kim, K.B.; Papadopoulos, N.E.; Homsi, J.; Hwu, P.; et al. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol. Immunother. 2017, 66, 1359–1366.
  81. Clinical trials.gov. A single arm study of Ipilimumab monotherapy in patients with previously treated unresectable stage III or IV melanoma (NCT00289627). Available online: (accessed on 26 November 2019).
  82. O’Day, S.J.; Maio, M.; Chiarion-Sileni, V.; Gajewski, T.F.; Pehamberger, H.; Bondarenko, I.N.; Queirolo, P.; Lundgren, L.; Mikhailov, S.; Roman, L.; et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann. Oncol. 2010, 21, 1712–1717.
  83. Clinical trails.gov. Autologous TriMix-DC therapeutic vaccine in combination with Ipilimumab in patients with previously treated unresectable stage III or IV melanoma (TriMix-Ipi) (NCT01302496). Available online: (accessed on 26 November 2019).
  84. Wilgenhof, S.; Corthals, J.; Heirman, C.; van Baren, N.; Lucas, S.; Kvistborg, P.; Thielemans, K.; Neyns, B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 2016, 34, 1330–1338.
  85. Clinical trials.gov. GEM study: Radiation and Yervoy in patients with melanoma and brain metastatses (GRAY-B) (NCT02115139). Available online: (accessed on 26 November 2019).
  86. Lopez-Martin, J.A.; Arance, A.M.; de la Cruz-Merino, L.; Illescas, A.; Valduvieco, I.; Berrocal, A.; Lopez Torrecila, J.; Marquez Rodas, I.; Garcia, M.; Soriano, V.; et al. Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22). J. Clin. Oncol. 2018, 36, 9546.
  87. Mortier, L.; Jamme, P.; Lacour, J.P.; Robert, C.; Lesimple, T.; Thomas, L.; Machet, L.; Saiag, P.; Lebbe, C.; Dutriaux, C.; et al. Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial. J. Clin. Oncol. 2018, 36, 9520.
  88. Hersh, E.M.; O’Day, S.J.; Powderly, J.; Khan, K.D.; Pavlick, A.C.; Cranmer, L.D.; Samlowski, W.E.; Nichol, G.M.; Yellin, M.J.; Weber, J.S. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investig. New Drugs 2011, 29, 489–498.
  89. Andtbacka, R.H.I.; Ross, M.I.; Agarwala, S.S.; Taylor, M.H.; Vetto, J.T.; Neves, R.I.; Daud, A.; Khong, H.T.; Ungerleider, R.S.; Tanaka, M.; et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J. Clin. Oncol. 2017, 35, 9510.
  90. Maio, M.; Grob, J.J.; Aamdal, S.; Bondarenko, I.; Robert, C.; Thomas, L.; Garbe, C.; Chiarion-Sileni, V.; Testori, A.; Chen, T.T.; et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 2015, 33, 1191–1196.
  91. McDermott, D.; Haanen, J.; Chen, T.T.; Lorigan, P.; O’Day, S. MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol. 2013, 24, 2694–2698.
  92. Ascierto, P.A.; Del Vecchio, M.; Robert, C.; Mackiewicz, A.; Chiarion-Sileni, V.; Arance, A.; Lebbé, C.; Bastholt, L.; Hamid, O.; Rutkowski, P.; et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017, 18, 611–622.
  93. Chesney, J.; Puzanov, I.; Collichio, F.; Singh, P.; Milhem, M.M.; Glaspy, J.; Hamid, O.; Ross, M.; Friedlander, P.; Garbe, C.; et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with Ipilimumab versus Ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 2018, 36, 1658–1667.
  94. Hiniker, S.M.; Reddy, S.A.; Maecker, H.T.; Subrahmanyam, P.B.; Rosenberg-Hasson, Y.; Swetter, S.M.; Saha, S.; Shura, L.; Knox, S.J. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 2016, 96, 578–588.
  95. Hodi, F.S.; Lee, S.; McDermott, D.F.; Rao, U.N.; Butterfield, L.H.; Tarhini, A.A.; Leming, P.; Puzanov, I.; Shin, D.; Kirkwood, J.M. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA 2014, 312, 1744–1753.
  96. Eggermont, A.M.; Chiarion-Sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M.; et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 2016, 375, 1845–1855.
  97. Schwarze, J.K.; Vandersleyen, V.; Awada, G.; Jansen, Y.; Seremet, T.; Neyns, B. A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM). J. Clin. Oncol. 2019, 37, 9585.
  98. Spicer, J.F.; Marabelle, A.; Baurain, J.; Awada, A.; Kristeleit, R.S.; Jossang, D.E.; Jebsen, N.; Loirat, D.; Armstrong, A.C.; Curigliano, G.; et al. A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors. J. Clin. Oncol. 2018, 36, 3094.
  99. Marabelle, A.; Baurain, J.; Awada, A.; Kristeleit, R.S.; Loirat, D.; Jossang, D.E.; Jebsen, N.L.; Sveinbjornsson, B.; Rekdal, O.; Gjerstad, V.S.; et al. A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma. In Proceedings of the American Association for Cancer Research Annual Meeting 2019, Atlanta, GA, USA, 29 March–3 April 2019. Abstract no: CT069.
  100. Hodi, F.S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.; Rutkowski, P.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19, 1480–1492.
  101. Callahan, M.K.; Kluger, H.; Postow, M.A.; Segal, N.H.; Lesokhin, A.; Atkins, M.B.; Kirkwood, J.M.; Krishnan, S.; Bhore, R.; Horak, C.; et al. Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study. J. Clin. Oncol. 2018, 36, 391–398.
  102. Long, G.V.; Atkinson, V.; Lo, S.; Sandhu, S.; Guminski, A.D.; Brown, M.P.; Wilmott, J.S.; Edwards, J.; Gonzalez, M.; Scolyer, R.A.; et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. Lancet Oncol. 2018, 19, 672–681.
  103. Atkins, M.B.; Hodi, F.S.; Thompson, J.A.; McDermott, D.F.; Hwu, W.J.; Lawrence, D.P.; Dawson, N.A.; Wong, D.J.; Bhatia, S.; James, M.; et al. Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: Dose-finding results from the phase Ib KEYNOTE-029 study. Clin. Cancer Res. 2018, 24, 1805–1815.
  104. Hodi, F.S.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.F.; McDermott, D.F.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016, 17, 1558–1568.
  105. Weber, J.S.; Gibney, G.; Sullivan, R.J.; Sosman, J.A.; Slingluff, C.L., Jr.; Lawrence, D.P.; Logan, T.F.; Schuchter, L.M.; Nair, S.; Fecher, L.; et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial. Lancet Oncol. 2016, 17, 943–955.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback